HBM HOLDINGS-B (02142) has announced the signing of an exclusive licensing agreement and an equity cooperation agreement with Solstice Oncology, a clinical-stage biotechnology company established by several major venture capital firms. Under these agreements, HBM HOLDINGS-B has granted Solstice Oncology exclusive rights to develop and commercialize its clinical-stage asset, HBM4003, in territories outside Greater China.

According to the terms, HBM HOLDINGS-B is eligible to receive upfront consideration valued at over $105 million. This includes an initial payment of $50 million, a near-term payment of $5 million, and the issuance of equity in Solstice Oncology worth more than $50 million. Additionally, the company may receive up to approximately $1.1 billion in additional development, regulatory, and commercial milestone payments, contingent on the achievement of certain future events, as well as tiered royalties based on net sales of HBM4003 outside Greater China.

HBM HOLDINGS-B intends to leverage this opportunity to strengthen its global collaboration network through innovative partnership models, maximizing the scientific and commercial value of its technology platform. The agreements are expected to accelerate the global development and commercialization of HBM4003 outside Greater China by establishing a dedicated global biotechnology company in collaboration with experienced investors. This cooperation model not only facilitates long-term value creation but also enables HBM HOLDINGS-B to actively participate in and drive the global development of the asset.